M.D. Anderson Cancer Center
To learn if SAR445877 can help to control locally advanced or metastatic NSCLC in patients who have previously received ICI therapy.
Primary Objectives * To identify early efficacy signals for SAR445877 in ICI-exposed NSCLC participants * Identify biomarkers related to the mechanism of action in SAR445877 and predictive of response/resistance in ICI-exposed NSCLC participants
Eligibility Criteria 1. Ability to understand and willingness to sign informed consent form (ICF) prior to initiation of the study and any study procedures. 2. Age ≥18 years. Because no dosing or adverse event data are currently available on the use of SAR445877 in participants \<18 years of age, children are excluded from this study. 3. Participants with histologically documented locally advanced or metastatic NSCLC who have had disease progression after treatment with all available therapies for metastatic disease that are known to confer clinical benefit, or are intolerant to treatment, or…
Given by IV
Arctuva estimate
Verify or correct the compensation shown for this listing.